NEW YORK, NY / ACCESSWIRE / July 18, 2018 / U.S. stocks closed up on Tuesday, as the Federal Reserve announced that it would be flexible in the face of changing conditions and will not move too quickly on changing monetary policy. Fresh round of corporate earnings along with central bank's comforting words help lift market enthusiasm. The Dow Jones Industrial Average gained 0.22 percent to close at 25,119.89, while the S&P 500 Index was up 0.40 percent to close at 2,809.55. The Nasdaq Composite Index increased 0.63 percent to close at 7,855.12.
"We've had a lull in trade talk, which has allowed investors to focus on earnings. In order for earnings to really provide a boost to stocks, we'd have to exceed expectations, and the potential for that is there," said chief market strategist at Ameriprise Financial, David Joy. "Recent momentum has been positive," he added.
RDI Initiates Coverage on:
Cara Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cara Therapeutics's stock moved 2.08% higher Tuesday, to close the day at $21.60. The stock recorded a trading volume of 479,369 shares, which was below its three months average volume of 1,277,936 shares. In the last year, Cara Therapeutics's shares have traded in a range of 11.11 - 22.29. The share price has gained 94.42% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $17.81 is above its 200-day moving average of $14.30. Shares of Cara Therapeutics have gained roughly 28.57 percent in the past month and are up 76.47 percent year-to-date.
Access RDI's Cara Therapeutics, Inc. Research Report at:
On Tuesday, shares of Cellectar Biosciences recorded a trading volume of 2,962,163 shares, which was above the three months average volume of 433,333 shares. The stock ended the day 1.47% lower at $7.38. The share price has fallen 42.16% from its 52 week high with a 52 week trading range of 0.57 - 12.76. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.82 is below its 200-day moving average of $1.08. Shares of Cellectar Biosciences have fallen roughly 22.32 percent in the past month and are down 46.13 percent year-to-date.
Access RDI's Cellectar Biosciences, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.